Critical Commentary takes a deep dive into one argument on a systemic problem in autoimmune drug development - trial design, regulatory strategy, industry incentives, or the gap between evidence and practice.
This is also my first paywalled issue. Check with your division or company; many folks have already subscribed using professional development or expense account funds!
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.